

**Amended claims for IPER/Chapter II (clean)Claims**

1. A composition comprising
  - a. a human IL-12 protein comprising a first IL-12 subunit and a second IL-12 protein subunit;
  - b. a ~~peptide or~~ protein comprising an EDB binding domain; and
  - c. a linker between the IL-12 protein and the ~~peptide or~~ protein comprising the EDB binding domain;

wherein the composition comprises:

- a p40 domain linked to a p35 domain by a first linker;
- a first L19 VH domain linked to the p35 domain by a SAD linker;
- a first L19 VL domain linked to the first L19 VH domain by a third linker;
- a second L19 VH domain linked to the first L19 VL domain by a fourth linker;
- a second L19 VL domain linked to the second L19 VH domain by a fifth linker;

and wherein the composition has a full length sequence according to SEQ ID NO: 16.

2. Use of the composition according to claim 1 ~~-(for the manufacture of a medicament) in~~ for the treatment of a human or animal subject;

- being diagnosed ~~for~~ with,
- suffering from, or
- being at risk of developing;

~~developing~~ a neoplastic disease, or for the prevention of ~~such condition~~ a neoplastic disease.

3. The use of claim 2, wherein the neoplastic disease is selected from the group consisting of malignant melanoma, non-small cell lung cancer (NSCLC), renal cell carcinoma, urothelial carcinoma, head and neck squamous cell carcinoma (HNSCC), microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer, hepatocellular

cancer, gastric cancer, squamous cell carcinoma of the skin, cervical cancer, and diffuse large B-cell lymphoma (DLBCL).

4. Use of the composition according to claim 1—~~(for in the manufacture of a medicament)~~ for the ~~inhibition~~ treatment of angiogenesis ~~in a human or animal subject~~ by tumor cells in cancer progression.

5. A pharmaceutical composition comprising the composition according to claim 1, and one or more pharmaceutically acceptable excipients.

6. A combination comprising (ia) the composition according to claim 1 or the pharmaceutical composition according to claim 5 and (iib) one or more therapeutically active compounds.

7. ~~A method for treating or preventing a disorder or condition associated with expression or overexpression of ED-B fibronectin, comprising administering to a subject in need thereof an effective amount~~ Use of the composition according to claim 1, the pharmaceutical composition according to claim 5, or the combination according to claim 6, in the manufacture of a medicament for the treatment of a disorder associated with overexpression of ED-B fibronectin.

8. A therapeutic kit of parts comprising:

- a) the composition according to claim 1, the pharmaceutical composition according to claim 5, or the combination according to claim 6
- b) an apparatus for administering the composition, pharmaceutical composition or combination, and
- c) instructions for use.